T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Coeur Mining
CDE
$18.9B
| $144M | 0.02% |
8,074,246
-1,352,287
| -14% | -$23.5M |
|
552
T. Rowe Price Equity Income ETF
TEQI
$470M
| $144M | 0.02% |
3,184,954
+530,853
| +20% | +$23.4M |
|
553
Agnico Eagle Mines
AEM
$91B
| $144M | 0.02% |
848,243
+5,507
| +0.7% | +$926K |
|
554
CG Oncology
CGON
$6.71B
| $143M | 0.02% |
3,443,144
+1,854,386
| +117% | +$76.7M |
|
|
BELFB
555
Bel Fuse Inc Class B
BELFB
$4.25B
| $142M | 0.02% |
834,261
+355,563
| +74% | +$55.6M |
|
556
DTE Energy
DTE
$28.9B
| $141M | 0.02% |
1,095,466
-7,913
| -0.7% | -$1.07M |
|
557
Illinois Tool Works
ITW
$82.3B
| $141M | 0.02% |
573,331
-116,599
| -17% | -$29M |
|
558
Biogen
BIIB
$31B
| $139M | 0.02% |
792,071
-173,386
| -18% | -$28.3M |
|
559
Sanofi
SNY
$105B
| $139M | 0.02% |
2,873,659
-2,999,880
| -51% | -$149M |
|
560
Louisiana-Pacific
LPX
$5.19B
| $139M | 0.02% |
1,723,824
+332,794
| +24% | +$28.1M |
|
561
Workday
WDAY
$43.3B
| $138M | 0.01% |
644,227
-74,162
| -10% | -$16.9M |
|
|
KRMN
562
Karman Holdings
KRMN
$7.99B
| $138M | 0.01% |
1,887,736
-313,580
| -14% | -$22.7M |
|
563
Expedia Group
EXPE
$38.8B
| $138M | 0.01% |
486,487
+39,339
| +9% | +$9.72M |
|
564
Toro Company
TTC
$9.26B
| $138M | 0.01% |
1,748,621
+228,532
| +15% | +$16.9M |
|
565
Teck Resources
TECK
$31.6B
| $137M | 0.01% |
2,854,516
-1,806,321
| -39% | -$78.2M |
|
|
RAL
566
Ralliant Corp
RAL
$8.03B
| $136M | 0.01% |
2,675,717
-721,344
| -21% | -$33.8M |
|
567
Moog Inc Class A
MOG.A
$13.5B
| $136M | 0.01% |
556,801
+196,126
| +54% | +$43.1M |
|
568
Disc Medicine
IRON
$3.06B
| $135M | 0.01% |
1,698,005
+371,576
| +28% | +$31.4M |
|
569
TC Energy
TRP
$65.8B
| $134M | 0.01% |
2,430,992
-311,892
| -11% | -$16.6M |
|
570
Huazhu Hotels Group
HTHT
$12.5B
| $131M | 0.01% |
2,790,935
-15,478
| -0.6% | -$668K |
|
571
Krystal Biotech
KRYS
$9.85B
| $131M | 0.01% |
529,955
+62,897
| +13% | +$13.2M |
|
572
Enova International
ENVA
$6.47B
| $131M | 0.01% |
830,887
+447,863
| +117% | +$58.3M |
|
|
CAI
573
Caris Life Sciences
CAI
$6.38B
| $130M | 0.01% |
4,827,965
-2,096,780
| -30% | -$59.1M |
|
574
Ero Copper
ERO
$3.63B
| $130M | 0.01% |
4,596,050
-2,487,818
| -35% | -$57.9M |
|
575
Mattel
MAT
$4.19B
| $130M | 0.01% |
6,528,281
-1,228,455
| -16% | -$23.7M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.